Comparative Trends in Statin Utilization and Expenditures in the Public and Private Healthcare Sectors in Malaysia: Insights From the Malaysian Statistics on Medicines, 2004-2022 - PubMed
5 hours ago
- #Malaysia
- #statin utilization
- #healthcare expenditure
- The study compares statin utilization and expenditures between Malaysia's public and private healthcare sectors from 2004 to 2022.
- Statin utilization increased in both sectors, with stronger growth in the public sector.
- Atorvastatin showed the highest growth rate in the public sector (25.27% annually), while rosuvastatin grew fastest in the private sector (13.09% annually).
- Significant cost per DDD differences were observed between the two sectors, with the public sector improving cost efficiency over time.
- The private sector had persistently high expenditures, particularly for rosuvastatin.
- The study recommends targeted measures to promote generic uptake and address pricing disparities for equitable statin access.